Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation: A cross-sectional study

BMJ Open

Volumn 3, Issue 9, 2013, Pages

  MacCallum, Peter K ^a,b   Mathur, Rohini ^a   Hull, Sally A ^a   Saja, Khalid ^c   Green, Laura ^b,d   Morris, Joan K ^a   Ashman, Neil ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b BARTS HEALTH NHS TRUST   (United Kingdom)

^c HAVERING AND REDBRIDGE UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^d NHS BLOOD AND TRANSPLANT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; DABIGATRAN; RIVAROXABAN; WARFARIN;

ADULT; AGED; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CREATININE CLEARANCE; CROSS-SECTIONAL STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; FEMALE; GENERAL PRACTITIONER; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY CLEARANCE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MODIFIED DIET IN RENAL DISEASE EQUATION; PATIENT SAFETY; PRESCRIPTION; PRIMARY MEDICAL CARE; SCORING SYSTEM; UNITED KINGDOM;

EID: 84885341223     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-003343     Document Type: Article

References (31)

1. NICE. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation. NICE technology appraisal guidance 249. NICE technology appraisal guidance 249, 2012. http://www.nice.org.uk/ta249
2. NICE. Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation. NICE technology appraisal guidance 256, 2012. http://www.nice.org.uk/ta256
3. SMC. Dabigatran etexilate 110 mg and 150 mg hard capsules (Pradaxa) SMC No. (672/11). Scottish Medicines Consortium, 2011. http://www.scottishmedicines.org.uk/SMC-Advice/Advice/672-11-dabigatran-Pradaxa/dabigatran-Pradaxa
4. SMC. Rivaroxaban 15 and 20 mg film-coated tablets (Xarelto) SMC No. (756/12). Scottish Medicines Consortium, 2012. http://www.scottishmedicines.org.uk/SMC-Advice/Advice/756-12-rivaroxaban-Xarelto-atrial/rivaroxaban-Xarelto-atrial
5. Connolly SJ, Ezekowitz MD, Yusuf S, et al Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
6. Patel MR, Mahaffey KW, Garg J, et al Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.
7. Camm AJ, Lip GY, De C.R., et al 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719-47.
8. Stangier J, Rathgen K, Stahle H., et al The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;64:292-303. (Pubitemid 47283865)
9. Bayer plc. Xarelto 20 mg film-coated tablets. Summary of Product Characteristics, 2012. http://www.medicines.org.uk/emc/medicine/25586/SPC
10. NKDEP. Chronic Kidney Disease and Drug Dosing: Information for Providers. National Kidney Disease Education Programe, 2010; http://nkdep.nih.gov/resources/ckd-drug-dosing-508.pdf
11. Boehringer Ingelheim Limited. Pradaxa 150 mg hard capsules. Summary of Product Characteristics, 2012. http://www.medicines.org.uk/emc/medicine/24839
12. Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med 2012;366:864-6.
13. MHRA. Drug safety update. Dabigatran (Pradaxa): risk of serious haemorrhage-contraindications clarified and reminder to monitor renal function. Med Healthc Prod Regul Agency 2012;5.
14. MHRA. Drug safety update. Dabigatran (Pradaxa): risk of serious haemorrhage-need for renal function testing. Med Healthc Prod Regul Agency 2011;5:5A2.
15. Department of Health. Chronic kidney disease, acute renal failure and end of life care. National Service Framework for Renal Services - Part Two, 2005. https://www.gov.uk/government/uploads/system/uploads/attachment-data/file/199002/National-Service-Framework-for-Renal-Services-Part-Two-Chronic-Kidney-Disease-Acute-Renal-Failure-and-End-of-Life-Care.pdf
16. Lip GY, Andreotti F, Fauchier L., et al Bleeding risk assessment and management in atrial fibrillation patients. Executive summary of a position document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on thrombosis. Thromb Haemost 2011;106:997-1011.
17. Dreyer G, Hull S, Aitken Z., et al The effect of ethnicity on the prevalence of diabetes and associated chronic kidney disease. QJM 2009;102:261-9.
18. Camm AJ, Kirchhof P, Lip G.Y., et al Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-429.
19. Hellden A, Odar-Cederlof I, Nilsson G., et al Renal function estimations and dose recommendations for dabigatran, gabapentin and valaciclovir: a data simulation study focused on the elderly. BMJ Open 2013;3:e002686.
20. Poli D, Testa S, Antonucci E., et al Bleeding and stroke risk in a real-world prospective primary prevention cohort of patients with atrial fibrillation. Chest 2011;140:918-24.
21. Marinigh R, Lane DA, Lip GY Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol 2011;57:1339-48.
22. Olesen JB, Lip GY, Kamper A.L., et al Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012;367:625-35.
23. Fox KA, Piccini JP, Wojdyla D, et al Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011;32:2387-94.
24. Lim W, Dentali F, Eikelboom J.W., et al Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006;144:673-84. (Pubitemid 46780653)
25. BNF. British National Formulary No. 64: September 2012. Royal Pharmaceutical Society. 2012.
26. Hudson JQ, Nyman HA Use of estimated glomerular filtration rate for drug dosing in the chronic kidney disease patient. Curr Opin Nephrol Hypertens 2011;20:482-91.
27. Golik MV, Lawrence KR Comparison of dosing recommendations for antimicrobial drugs based on two methods for assessing kidney function: Cockcroft-Gault and modification of diet in renal disease. Pharmacotherapy 2008;28:1125-32.
28. Scowcroft AC, Lee S, Mant J. Thromboprophylaxis of elderly patients with AF in the UK: an analysis using the General Practice Research Database (GPRD) 2000-2009. Heart 2013;99:127-32.
29. Cowan C, Fay M, Griffith K., et al Anticoagulation in AF. Anticoagulation uptake remains poor in high risk patients. BMJ 2011;342:d1153.
30. Holt TA, Thorogood M, Griffiths F. Changing clinical practice through patient specific reminders available at the time of the clinical encounter: systematic review and meta-analysis. J Gen Intern Med 2012;27:974-84.
31. Poli D, Antonucci E, Zanazzi M., et al Impact of glomerular filtration estimate on bleeding risk in very old patients treated with vitamin K antagonists. Results of EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics). Thromb Haemost 2012;107:1100-6.